News and Updates

Novartis discontinues its FSHD muscular dystrophy drug, ladademirsen, after the AOC therapy failed to meet primary endpoints in a Phase 2 clinical trial.

New clinical results for TeaRx Red Eye show high accuracy in identifying Allergic Conjunctivitis through Total Tear IgE biomarker testing. Learn more.

CAMP4 Therapeutics plans to launch a genetic disorder clinical trial in the UK by late 2026, leveraging novel RNA-targeting technology for precision therapy.

Medicus Pharma announces positive Phase 2 results for SkinJect®, a non-surgical treatment for basal cell carcinoma. Read the latest clinical trial update.

Clinical trial access for bladder cancer remains unequal. Expert María Natalia Gandur Quiroga discusses the urgent need to bridge regional research gaps.

A new Phase 1/2 clinical trial for OPGx-BEST1 reveals promising safety and efficacy results for patients with inherited retinal diseases. Learn more here.

A decline in clinical academics is threatening the UK’s medical research pipeline. Discover why experts fear for the future of life-saving innovation.

Labcorp strengthens its global clinical trial capacity by acquiring MLM Medical Labs, aiming to accelerate drug development and biomarker research worldwide.

Structural heart trials often overlook female biology. Discover why experts are demanding inclusive research to close the gender gap in cardiac care.

Researchers have achieved a breakthrough with a new oral insulin pill, potentially eliminating the need for daily injections for diabetes patients.